31.16
Zenas Biopharma Inc stock is traded at $31.16, with a volume of 122.80K.
It is down -0.16% in the last 24 hours and up +43.75% over the past month.
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.
See More
Previous Close:
$31.33
Open:
$30.33
24h Volume:
122.80K
Relative Volume:
0.35
Market Cap:
$1.32B
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+3.61%
1M Performance:
+43.75%
6M Performance:
+162.42%
1Y Performance:
+56.79%
Zenas Biopharma Inc Stock (ZBIO) Company Profile
Name
Zenas Biopharma Inc
Sector
Industry
Phone
857-271-2954
Address
852 WINTER STREET, SUITE 250, WALTHAM
Compare ZBIO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
ZBIO
Zenas Biopharma Inc
|
31.28 | 1.48B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.97 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.15 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
425.94 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
840.46 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
185.00 | 39.72B | 447.02M | -1.18B | -868.57M | -6.1812 |
Zenas Biopharma Inc Stock (ZBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-20-25 | Initiated | Wedbush | Outperform |
| Feb-04-25 | Initiated | Wolfe Research | Outperform |
| Dec-16-24 | Initiated | H.C. Wainwright | Buy |
| Nov-05-24 | Initiated | Rodman & Renshaw | Buy |
| Oct-08-24 | Initiated | Citigroup | Buy |
| Oct-08-24 | Initiated | Guggenheim | Buy |
| Oct-08-24 | Initiated | Jefferies | Buy |
| Oct-08-24 | Initiated | Morgan Stanley | Overweight |
View All
Zenas Biopharma Inc Stock (ZBIO) Latest News
Will Zenas BioPharma Inc. stock sustain high P E ratiosJuly 2025 PreEarnings & Reliable Breakout Stock Forecasts - newser.com
Will Zenas BioPharma Inc. benefit from macro trendsMarket Rally & Long-Term Safe Investment Ideas - newser.com
Is Zenas BioPharma Inc. stock a dividend growth opportunityPortfolio Return Report & Real-Time Stock Movement Alerts - newser.com
How risky is Zenas BioPharma Inc. stock nowEarnings Risk Report & Real-Time Volume Spike Alerts - newser.com
What dividend safety score for Zenas BioPharma Inc. stockJuly 2025 Summary & Stock Timing and Entry Methods - newser.com
Price momentum metrics for Zenas BioPharma Inc. explainedWeekly Market Report & Reliable Price Breakout Signals - newser.com
How to track smart money flows in Zenas BioPharma Inc.Dollar Strength & Fast Entry High Yield Stock Tips - newser.com
Multi asset correlation models including Zenas BioPharma Inc.2025 Price Momentum & Weekly Hot Stock Watchlists - newser.com
How to build a dashboard for Zenas BioPharma Inc. stockJuly 2025 Volume & Real-Time Stock Price Movement Reports - newser.com
Applying chart zones and confluence areas to Zenas BioPharma Inc.July 2025 Closing Moves & Reliable Volume Spike Trade Alerts - newser.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Zenas BioPharma, Inc. (ZBIO) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
How Zenas BioPharma Inc. stock reacts to inflationary pressuresMarket Growth Review & Low Risk Entry Point Tips - newser.com
Has Zenas BioPharma Inc. formed a bullish divergenceTrade Analysis Report & Weekly Momentum Picks - newser.com
Is Zenas BioPharma Inc. stock ready for breakoutQuarterly Portfolio Review & High Conviction Trade Alerts - newser.com
Leading vs lagging indicators on Zenas BioPharma Inc. performanceJuly 2025 Outlook & Daily Growth Stock Investment Tips - newser.com
Citigroup Raises Zenas BioPharma (NASDAQ:ZBIO) Price Target to $46.00 - MarketBeat
Zenas BioPharma, Inc.Common Stock (Nasdaq:ZBIO) Stock Quote - FinancialContent
Weiss Ratings Reiterates Sell (E+) Rating for Zenas BioPharma (NASDAQ:ZBIO) - MarketBeat
HC Wainwright Reduces Earnings Estimates for Zenas BioPharma - MarketBeat
Strategies to average down on Zenas BioPharma Inc.Insider Selling & Technical Entry and Exit Tips - newser.com
Published on: 2025-10-31 01:53:58 - newser.com
Zenas BioPharma (NASDAQ:ZBIO) Shares Down 7.3%Here's What Happened - MarketBeat
Is Zenas BioPharma Inc a good long term investmentPortfolio Allocation Tips & Free Phenomenal Trading Returns - earlytimes.in
Zenas BioPharma (ZBIO) Price Target Increased by 21.59% to 40.22 - MSN
Promising Phase 2 Results and Strategic Licensing Drive Buy Rating for Zenas BioPharma - TipRanks
Zenas BioPharma (NASDAQ:ZBIO) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
Zenas BioPharma (NASDAQ:ZBIO) Given Outperform Rating at Wedbush - MarketBeat
Zenas BioPharma, Inc. (NASDAQ:ZBIO) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
HC Wainwright & Co. Maintains Zenas BioPharma (ZBIO) Buy Recommendation - MSN
Zenas BioPharma (NASDAQ:ZBIO) Shares Gap UpWhat's Next? - MarketBeat
1 Trial, 2 Franchises: Zenas Stock Climbs on Landmark Data - sharewise.com
ZBIO: Citigroup Raises Price Target, Maintains Buy Rating | ZBIO Stock News - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Zenas BioPharma, Inc. (ZBIO) And Encourages Stockholders to Reach Out - ACCESS Newswire
ZBIO: Morgan Stanley Raises Price Target, Maintains Overweight R - GuruFocus
Zenas BioPharma, Inc. (ZBIO) Stock Price, News, Quote & History - Yahoo! Finance Canada
Zenas Biopharma Inc Stock (ZBIO) Financials Data
There is no financial data for Zenas Biopharma Inc (ZBIO). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Zenas Biopharma Inc Stock (ZBIO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| SR ONE CAPITAL MANAGEMENT, LLC | 10% Owner |
Oct 09 '25 |
Buy |
19.00 |
126,315 |
2,399,985 |
1,917,895 |
| ENRIGHT PATRICK G | Director |
Oct 09 '25 |
Buy |
19.00 |
105,265 |
2,000,035 |
1,832,669 |
| ENRIGHT PATRICK G | Director |
Oct 09 '25 |
Buy |
20.85 |
11,990 |
249,992 |
11,990 |
| MOULDER LEON O JR | See Remarks |
Oct 07 '25 |
Buy |
20.85 |
36,928 |
769,949 |
36,928 |
| Fairmount Funds Management LLC | Director |
Oct 07 '25 |
Buy |
19.00 |
316,219 |
6,008,161 |
2,209,025 |
| Lu Hongbo | Director |
Oct 07 '25 |
Buy |
19.00 |
263,160 |
5,000,040 |
321,983 |
| MOULDER LEON O JR | Chief Executive Officer |
Feb 18 '25 |
Buy |
6.67 |
25,000 |
166,750 |
266,155 |
| Xiao Ting | Director |
Feb 07 '25 |
Buy |
7.76 |
10,000 |
77,600 |
47,000 |
| MOULDER LEON O JR | Chief Executive Officer |
Dec 04 '24 |
Buy |
9.98 |
45,000 |
449,100 |
241,155 |
| MOULDER LEON O JR | Chief Executive Officer |
Dec 03 '24 |
Buy |
10.76 |
25,000 |
269,000 |
196,155 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):